Aralez Pharma Stock Analysis (NASDAQ:ARLZ)

Add to My Stocks
$4.4 $0.34 (8.37%) ARLZ stock closing price Jan 20, 2017 (Closing)
Watch Robo Advisor Video of ARLZ Stock Analysis
Aralez Pharma
Updated on : Jan 20, 2017
previous close
ARLZ 4.4 (0%)
S&P 500 2271.3 (0%)
Closing Price On: Jan 20, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q3
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
-1.3%
Operating Profit
Operating Margin:
-219.9%
Sector Average:
-1.3%
5 Quarter Net Profit
Net Margins
2016-Q3
%
LTM Margin
Debt/Equity Ratio
Debt:
74.5M
Debt/Equity Ratio:
 0.5
Compared to the industry
Cash Flow
Operating cash flow:
-$10.9M
Net Income:
-$20.6M
PROS      CONS
Recent Growth
Long Term Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
ROE
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
ARLZ PS :
7.1
Industry PS :
4.5
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-93.3%
Return on Equity:
-77.7%
Free Cash Flow Margin:
-90.2%
Double Tap To Exit Full Screen
0:00
/

Aralez Pharma Analysis Video

140 5 2

View Aralez Pharma stock analysis video. This is our ARLZ analyst opinion covering the buy and sell arguments for ARLZ stock.

Aralez Pharmaceuticals Inc Stock Rating (1.9/5)

Our Aralez Pharma stock opinion is based on fundamentals of the company. This Aralez Pharma stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy ARLZ stock?

  • Aralez Pharma sales grew by 134.2% year on year in 2016 Q3.

Should you sell ARLZ stock?

  • The company saw an average annual sales decline of in sales over the last 5 years.
  • Aralez Pharma registered a negative operating margin of -219.9% (average) over the Trailing Twelve Months (TTM).
  • Over the last 12 months, Aralez Pharma had an average Net loss of -211.7%.
  • Aralez Pharma has a debt/equity ratio of  0.5, which is worse than the average in the Medical sector.
  • The lack of profits renders the PE ratio useless for ARLZ stock.
  • Aralez Pharma's negative ROIC of -93.3% indicates operational inefficiency.
  • Aralez Pharma has a negative return on equity of -77.7%. This indicates that the firm is inefficient at generating profits.
  • Aralez Pharma has a negative FCF (Free Cash Flow) margin of -90.2%.

Comments on this video and Aralez Pharma stock